上海凯屹医药科技

Kaiyi Pharma is a clinical-stage biotechnology company based in Shanghai, China, focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases and oncology. The company's lead candidate, KY-0501, is a highly selective thyroid hormone receptor beta (THR-β) agonist currently being evaluated in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Kaiyi Pharma leverages its expertise in medicinal chemistry and disease biology to target unmet medical needs in chronic metabolic conditions. The company is supported by prominent venture capital firms and maintains a pipeline of programs targeting metabolic and endocrine disorders.